JUNE 2022LIFE SCIENCES REVIEW 19inflammation within the tumor microenvironment (TME). By turning immuno suppressive cells into inflammatory or immuno reactive, the antibody increases the effect of T-cell migration and tumor infiltration and thereby drives anti-tumor responses. KVA12.1 can significantly decelerate the growth of cancer cells even in difficult to treat tumors by increasing monocyte differentiation and activation, improving HLA-dependent T cell activation, and reducing MDSC-mediated T-cell suppression. What makes this fully human engineered IgG1 monoclonal antibody more reliable is its ability to work with other cancer therapeutics, inducing chemotherapy and checkpoint inhibitors. "KVA12.1 is in preclinical development and will enter Phase 1 clinical studies in Q32022," adds Dr. Iadonato.KVA12.1 is being developed for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian. These initial target indications represent ~450,000 patients in the US annually.Kineta's portfolio also includes an exciting anti-CD27 agonist antibody program capable of addressing the critical problem associated with exhausted T-cells. Specifically designed to target the CD27 protein, the drug induces T-cell proliferation, natural killer cells activation, and secretion of cytokines, which provides the ability to potentiate new anti-tumor responses. The company is also developing a drug directed at CD24 protein. CD24 sends a "don't eat me" signal that prevents the immune system from detecting and killing cancer cells. Kineta's anti-CD24 monoclonal antibody blocks the CD24 signals and restores immune recognition of cancer cells, which in turn drives a strong immune response. "In essence, we explore the uncharted territories within the immuno-oncology space by targeting novel innate immune pathways to solve the problems of cancer resistance. We strive to advance innovations in cancer therapeutics that address treatment gaps and provide hope to the many patients with unmet needs," adds Dr. Iadonato. Value Delivered Beyond Cancer TherapeuticsIn addition to its pipeline of novel cancer immunotherapies, Kineta is developing a novel non-opioid for treating chronic neuropathic pain. The company has partnered with Genentech, a member of the Roche Group, to develop KCP506. KCP506 is a long-acting 910 nicotinic acetylcholine receptor (nAChR) antagonist for the treatment of chronic neuropathic pain. This first-in-class drug targets the innate immune system and nerve fibers in the peripheral nervous system to not only block pain signaling but to also prevent inflammation around injured nerves. The combination of analgesic, anti-neuroinflammatory, and neuroprotective effects provides KCP506 with the potential to be a disease-modifying therapy that may slow or halt the progression of chronic pain.Under the exclusive research collaboration and option agreement with Genentech, Kineta has received ~21 million dollars in upfront and milestone payments and is eligible to receive up to $359 million as the drug progresses through clinical and commercial milestones. KCP506 has successfully completed preclinical studies, where it demonstrated non-addictive and non-tolerizing characteristics and therefore may serve as a safer alternative to opioids or gabapentinoids. It is currently in Phase 1 clinical studies to evaluate the safety, tolerability, and pharmacokinetics of the drug.Heading towards a Unique MissionBehind the massive success of Kineta lies a world-class team of scientists, and industry veterans that share the same vision--creating a paradigm shift of next-generation cancer therapeutics. They adhere to a collaborative culture, an integrated cross-functional approach and are always open to creative ideas to address unmet needs in the market. The company prides itself on serving as the frontrunner in introducing and developing innovative therapies for critical diseases. Such ardent focus on innovation helps Kineta gain a competitive edge and explore new avenues of success. Today, the company is looking forward to establishing its footprints in the public markets and extending its global reach to regions in Asia, Europe, and North America. "We are always committed to expanding our immuno-oncology portfolio by leveraging our PiiONEERTM discovery platform. By 2024, we will have four new products in clinical development, including therapies for solid tumors and blood cancer," concludes Philips. We believe that having a strong innate immune response will lead to a strong T-cell response; and together they can build a powerful shield against tumor cells
< Page 9 | Page 11 >